StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for VYNE yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $0.67 | $0.67 | +0.09% | 0.1M |
| 05-15 | $0.67 | $0.67 | +0.03% | 0.1M |
| 05-18 | $0.67 | $0.68 | +0.94% | 0.7M |
| 05-19 | $0.67 | $0.68 | +1.51% | 0.1M |
| 05-20 | $0.68 | $0.68 | -1.07% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $86.00K | $570.00K | $271.00K | $202.00K |
Operating Income | $-3.82M | $-29.75M | $-16.74M | $-9.20M |
Net Income | $-3.58M | $-26.48M | $-14.37M | $-8.61M |
EPS (Diluted) | $-0.08 | $-0.62 | $-0.34 | $-0.20 |
Total Assets | $25.87M | $30.16M | $44.72M | $56.42M |
Total Liabilities | $1.24M | $2.40M | $5.84M | $12.29M |
Cash & Equivalents | $24.63M | $24.03M | $22.05M | $28.21M |
Free Cash Flow OCF − CapEx | Not available | $-33.12M | Not available | Not available |
Shares Outstanding | 33.35M | 33.32M | 19.77M | 15.96M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.